Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus. Issue 2 (8th January 2016)

• Record Type: Journal Article
• Authors: Ilag, L. L.; Deeg, M. A.; Costigan, T.; Hollander, P.; Blevins, T. C.; Edelman, S. V.; Konrad, R. J.; Ortmann, R. A.; Pollom, R. K.; Huster, W. J.; Zielonka, J. S.; Prince, M. J.
• Is Part Of: Diabetes, obesity & metabolism. Volume 18:Issue 2(2016)
• Page Start: 159
• Page End: 168
• Publication Date: 2016-01-08
• Subjects: biosimilar insulin -- insulin antibody -- insulin glargine -- LY2963016 insulin glargine; Diabetes -- Periodicals; Obesity -- Periodicals; Metabolism -- Disorders -- Periodicals; Clinical pharmacology -- Periodicals; 616.462
• DOI: 10.1111/dom.12584
• Languages: English
• ISSNs: 1462-8902

Abstract

Abstract : Aims: To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid sequences, in patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM). Methods: To assess immunogenicity, anti‐insulin glargine antibodies (measured as percent binding) were compared between treatments in 52‐week (open‐label) and 24‐week (double‐blind) randomized studies in total study populations of patients with T1DM (N = 535) and T2DM (N = 756), respectively, and two subgroups of patients with T2DM: insulin‐naïve patients and those reporting prestudy IGlar treatment (prior IGlar). Relationships between insulin antibody levels and clinical outcomes were assessed using analysis of covariance and partial correlations. Insulin antibody levels were assessed using Wilcoxon rank sum. Treatment comparisons for treatment‐emergent antibody response (TEAR) and incidence of detectable antibodies were analysed using Fisher's exact test. Results: No significant treatment differences were observed for insulin antibody levels, incidence of detectable anti‐insulin glargine antibodies, or incidence of TEAR [overall and endpoint, by last‐observation‐carried‐forward (LOCF)] in patients with T1DM or patients with T2DM, including the insulin‐naïve subgroup. A statistically significant difference was noted in the overall incidence of detectable antibodies but not at endpoint (LOCF) nor in TEAR for the prior IGlar subgroup of patients with T2DM. Insulin antibody levels were low (<5%) in both treatment groups. Insulin antibody levels or developing TEAR was not associated with clinical outcomes. Conclusions: LY IGlar and IGlar have similar immunogenicity profiles; anti‐insulin glargine antibody levels were low for both treatments, with no observed effect on efficacy and safety outcomes.